Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy - (N Engl J Med)
    Abacavir-Lamivudine Combination Has Worse Clinical Outcomes Than Tenofovir DF-Emtricitabine Combination in Patients With High HIV-1 Loads - (DGNews)
    Directly Observed Antiretroviral Therapy Offers No Benefit Over Self-Administered Treatment for Patients With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 11/23/2009 - (DGNews)
    TopAbstracts in AIDS and HIV 11/09/2009 - (DGNews)

    News archive

     Recent webcasts/CME - AIDS and HIV
      Prevention With Positives In HIV Medical Care
      Non-AIDS-Defining Cancers in Patients with HIV Infection
      Management of an HIV-Infected Patient After Initial Antiretroviral Regimen Failure
      The Use of Chemokine Receptor Antagonists in Antiretroviral Treatment Failure
      Issues in the Care of HIV and Hepatitis C Virus-coinfected Patients: Antiretroviral Pharmacokinetics, Drug Interactions, and Liver Transplantation

      Webcasts/CME archive

       Recent cases - AIDS and HIV
        Multicentric Castleman's Disease & HIV infection
        A Patient with Neck Pain and Fever
        Rapid and Persistent Selection of the K103N Mutation as a Majority Quasispecies in a HIV1-Patient Exposed to Efavirenz for Three Weeks: A Case Report and Review of the Literature
        Newly Formed Cystic Lesions for the Development of Pneumomediastinum in Pneumocystis Jirovecii Pneumonia
        Bordetella Bronchiseptica Pneumonia in a Man with Acquired Immunodeficiency Syndrome: A Case Report

        Cases archive
          




        my personal edition > aids and hiv > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Combination HIV Drug Trizivir, Along With Tenofovir, Well Tolerated: Presented at ICAAC

        By Paula Moyer

        WASHINGTON, DC -- December 22, 2005 -- In the near future, patients with HIV-1 who are taking their first antiretroviral therapy regimen may be able to manage their disease with a once-daily regimen that includes 1 tablet combining 3 antiretrovirals (Trizivir) and 1 tablet of tenofovir (Viread), according to research presented here at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

        "In subjects who are naïve to antiretroviral therapy, this treatment combination given as a once-daily regimen provided virologic suppression for subjects who remained on therapy," according to principal investigator Cal Cohen, MD, research director, Community Research Initiative of New England, and clinical instructor, Harvard Medical School, Boston, Massachusetts.

        The combination tablet contains 300 mg of abacavir (Ziagen), 300 mg of zidovudine (Retrovir), and 150 mg of lamivudine (Epivir).

        "Given the need for simple regimens with fewer drug interactions, a fully powered study is needed to establish the role of [such a] regimen for initial HIV treatment," Dr. Cohen said in a presentation on December 16th.

        He noted that additional protease inhibitor-sparing and nucleoside reverse transcriptase inhibitor-sparing therapeutic options are needed for several HIV populations, including women of childbearing age, patients with psychiatric illnesses, patients coinfected with hepatitis B or C, and patients on tuberculosis medications with rifampin-based therapy.

        The investigators conducted an open-label, multicenter study to evaluate the feasibility of using the combination pill Trizivir along with tenofovir, a regimen that consisted of 3 pills taken once daily.

        The 123 subjects had an HIV-1 RNA viral load of at least 30,000 c/mL at the time of study entry. In 13 subjects, the investigators assessed changes from baseline in fat distribution and bone density by whole body and regional dual energy x-ray absorptiometry (DEXA) at 1 site.

        Patients were a median of 38 years old (range 20-57 years), and 74% were asymptomatic. Among these patients, 83% were male and 46% were Caucasian, with 41% African American. The median viral load was 5.1 log10 copies/mL, with 59% having a viral load of at least 100,000 c/mL. The median CD4+ was 222 cells/mm3, with 45% having more than 200 cells/mm3.

        A total of 52 subjects withdrew early -- 14 for adverse events, 13 lost to follow-up, 12 for virologic nonresponse, and 13 for other reasons. A viral load of at least 400 c/mL at week 24 or later -- the study's definition of virologic failure -- was noted in 14 subjects (11%). The resistance rate to abacavir was 6.5%.

        At week 48, the intent-to-treat (ITT) analysis, involving 68 patients, showed that 41% achieved viral load < 50 c/mL and 51% achieved a viral load < 400 c/mL. The ITT observed analysis showed that 75% had a viral load of < 50 c/mL and 93% had a viral load < 400 c/mL. The median CD4+ change from baseline was an increase of 127 cells/mm3.

        By the end of the study, the median changes for fasting lipid levels were a decrease of 9 mg/dL for total cholesterol, an increase of 1 mg/dL for high-density lipoproteins, a decrease of -9 mg/dL for low-density lipoproteins, and a decrease of 4 mg/dL for triglycerides.

        In the subset of patients with body fat and bone density analysis, the median changes were a gain of 9% in arm fat, a gain of 11% in leg fat, and a gain of 14% in trunk fat. Bone mineral density was not changed.

        The investigators concluded that in antiretroviral therapy-naïve subjects, this once-daily regimen provided virologic suppression and improved fasting lipids, with neither lipoatrophy nor bone loss occurring in the subset of subjects undergoing DEXA.

        The approach may be useful as a way to minimize the use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors, the investigators concluded.


        [Presentation title: 48 Week Analysis of Efficacy and Safety of Once-Daily (QD) Abacavir/Lamivudine/Zidovudine (Trizivir) + Tenofovir (TDF). Abstract H-521]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send